Mild cognitive impairment and Alzheimer disease have a low prevalence among newly diagnosed patients with multiple sclerosis.

Cladribine treatment for relapsing multiple sclerosis improves health-related quality of life and preserves cognitive function after 4 years.

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.

Children with pediatric-onset multiple sclerosis (POMS) have shorter telomeres, suggesting MS may accelerate biological aging.

Efficacy of treatment is maintained during the switch from IV anti-CD20 therapies to ofatumumab in relapsing MS regardless of race/ethnicity.

Ocrelizumab treatment in Black and Hispanic patients with MS reduces NfL levels and prevents the forming of contrast-enhancing lesions and new or enlarging T2 lesions.

Higher ocrelizumab doses improve the benefit-risk profile among patients with relapsing multiple sclerosis treated with it for up to 10 years.

Among patients with relapsing multiple sclerosis, 450 mg of ublituximab could be safely infused in 30 minutes at week 24.

Sexual dysfunction and depression are common and associated with increased disability in patients with multiple sclerosis.

The risk of developing MS and other demyelinating diseases is 3 times greater in individuals diagnosed with EBV-positive IM.

Among stroke survivors, the risk of developing dementia after stroke is significantly high, highlighting the need for targeted prevention strategies.

The Alzheimer's Association revised the diagnostic criteria for Alzheimer disease (AD) and ADRD for clinicians in primary and specialty care.